Intellectual property
IFPMA fosters an understanding of the enabling role intellectual property (IP) plays in driving innovation in the pharmaceutical industry, ultimately making health breakthroughs happen.
Read more
Quality, safety, and efficacy of therapeutical products
IFPMA collaborates with the World Health Organization (WHO), regulatory, and other standard-setting bodies to share experience and scientific input and implement guidelines standardizing the quality of medicines and vaccines.
Read more
Biotherapeutics and advanced therapies
IFPMA spotlights how the innovative pharmaceutical industry is delivering a new generation of treatments while explaining the science-based regulatory requirements needed to make sure they deliver maximum therapeutic impact.
Read more
Antimicrobial resistance
IFPMA helps lead the innovative pharmaceutical industry’s work on antimicrobial resistance (AMR). We raise awareness of the unique challenges in combating AMR and of measures that could establish economic conditions favorable to long-term investment into antibiotic R&D.
Read more
Collaboration, convergence, and regulatory reliance
IFPMA acts as a convener and encourages dialogues with national regulatory authorities (NRAs), regional regulatory bodies, and global regulatory networks to address key regulatory hurdles and identify solutions to facilitate patients’ timely access to innovative therapies.
Read more
IFPMA Notes for Guidance
The purpose of the various IFPMA “Notes for Guidance” is to provide additional interpretation and further guidance in relation to the relevant provisions of the Code of Practice. Notes for Guidance are non-binding and must be read with the spirit of the Code in mind and always in accordance with applicable laws and regulations and other applicable industry codes.
Read more